InVision Medical Technology · Apr 2026
InVision announced a partnership with Dandelion Health to run its echo AI on Dandelion's Clinical AI Marketplace, generating up to 30x more cardiac measurements per patient from raw echocardiogram data.
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Y Combinator-backed medical technology company building FDA-cleared AI software for echocardiography and cardiac imaging, focused on automating measurements, structured reporting, and disease detection in existing hospital workflows.
Primary product
InVision Precision LVEF
Founded
2022
Headquarters
Los Angeles, California, United States
Team size
1-10
Industry
Medical Technology
Sub-industry
AI echocardiography software (Software as a Medical Device)
Offices
2 jobs at InVision Medical Technology
Business model
Stage
pre-seed
Total raised
$500K
Latest round
Pre-Seed Convertible Note · Aug 2022
Latest amount
$500K
Aug 2022 · Y Combinator
Investors
Clinician- and researcher-led, evidence-driven, and regulatory-conscious; the public materials emphasize peer-reviewed validation, workflow integration, and close collaboration between clinical and commercial teams.
Pricing
Enterprise pricing and reimbursement-backed clinical deployment; some products are positioned around CPT Category III code 0932T, while demos/briefings are offered for sales-led deployment.
Differentiators
Technology
Customers
Competitors
Estimated revenue
$2M-$5M (GetLatka estimates ~$2.1M ARR)
Estimated monthly visits
1.5K
InVision Medical Technology · Apr 2026
InVision announced a partnership with Dandelion Health to run its echo AI on Dandelion's Clinical AI Marketplace, generating up to 30x more cardiac measurements per patient from raw echocardiogram data.
InVision Medical Technology · Nov 2025
InVision said the FDA granted Breakthrough Device status to Precision Cirrhosis, its opportunistic detection tool for end-stage liver disease from routine echocardiography.
InVision Medical Technology · May 2025
InVision announced FDA 510(k) clearance for its cardiac amyloidosis detection SaMD, developed with support from Alexion, AstraZeneca Rare Disease.
InVision Medical Technology · Jul 2024
The company announced CPT Category III code 0932T, creating a reimbursement pathway for AI-assisted cardiac amyloidosis screening on echocardiography.
InVision Medical Technology · May 2024
InVision announced FDA 510(k) clearance for its automated left ventricular ejection fraction software for adult echocardiography.